Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6966MR)

This product GTTS-WQ6966MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6966MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3791MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ12900MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ6864MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ4962MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ9433MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ6999MR IVTScrip™ mRNA-Anti-CSF3R, F-627(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA F-627
GTTS-WQ6964MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ9413MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW